Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Inc.

Analysts have been eager to weigh in on the Energy sector with new ratings on Dorian LPG (LPG) and HF Sinclair Corporation (DINO). Dorian LPG (LPG)...

Analysts Have Conflicting Sentiments on These Energy Companies: Dorian LPG (LPG) and HF Sinclair Corporation (DINO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Vera Therapeutics (VER...

Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)

The latest announcement is out from Inovio Pharmaceuticals ( ($INO) ). On May 19, 2026, Inovio Pharmaceuticals amended its bylaws to refine its cor...

Inovio Shareholders Endorse Governance Changes and Leadership

An update from Nikon ( ($JP:7731) ) is now available. Nikon has approved a proposal to revise its stock compensation system for directors who are n...

Nikon Overhauls Director Stock Compensation to Align With New Strategy

An update from Nikon ( ($JP:7731) ) is now available. Nikon has approved the disposal of 7,686 shares of its treasury stock, valued at approximatel...

Nikon to Dispose of Treasury Stock for Performance-Based Executive Remuneration

Last week, stocks pushed to fresh highs as strong jobs data and gains in chip stocks helped lift the market. The S&P 500 (SPX) rose 0.84% to 7,397....

The Week That Was, The Week Ahead: Macro and Markets, May 10

Innodata ($INOD) stock skyrocketed over 92% on Friday, May 8, 2026, after reporting blowout first-quarter results that easily topped Wall Street ex...

Innodata Stock (INOD) Skyrocketed 92% on Friday – Here’s Why

There’s a lot to be optimistic about in the Energy sector as 2 analysts just weighed in on Vista Energy SAB de CV (VIST) and HF Sinclair Corporatio...

Analysts Offer Insights on Energy Companies: Vista Energy SAB de CV (VIST) and HF Sinclair Corporation (DINO)

In a report released today, Betty Zhang from Scotiabank maintained a Hold rating on HF Sinclair Corporation, with a price target of $54.00. Accordi...

Scotiabank Sticks to Their Hold Rating for HF Sinclair Corporation (DINO)

TD Cowen analyst Jason Gabelman maintained a Hold rating on HF Sinclair Corporation today and set a price target of $80.00. Gabelman covers the Ene...

TD Cowen Reaffirms Their Hold Rating on HF Sinclair Corporation (DINO)

In a report released on May 1, Theresa Chen from Barclays maintained a Hold rating on HF Sinclair Corporation, with a price target of $71.00. The c...

Barclays Remains a Hold on HF Sinclair Corporation (DINO)

HF Sinclair Corporation (($DINO)) has held its Q1 earnings call. Read on for the main highlights of the call. HF Sinclair’s latest earnings call pa...

HF Sinclair Earnings Call Signals Rebound Amid Risks

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Innodata (INOD) and Asure (ASUR) with bullish sentim...

Current Quarter	$-0.28	Next Quarter	$-0.25
Current Year	$-0.98	Next Year	$-0.49
QoQ Growth	+10.7%	YoY Growth	+50.0%
3Y EPS CAGR	+49.5%	Target Price	$5.96
Consensus	Buy	Upside	+373.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INO	$1.26	-6.67%	2.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INO	$1.26	-6.7%	2.12M
3
4
5
6

INO

INO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Inovio Pharmaceuticals Inc. Data in Excel

Get Inovio Pharmaceuticals Inc. Data in Excel